Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Dona, C; Koschutnik, M; Nitsche, C; Winter, MP; Seidl, V; Siller-Matula, J; Mach, M; Andreas, M; Bartko, P; Kammerlander, AA; Goliasch, G; Lang, IRE; Hengstenberg, C; Mascherbauer, J.
Cerebral Protection in TAVR-Can We Do Without? A Real-World All-Comer Intention-to-Treat Study-Impact on Stroke Rate, Length of Hospital Stay, and Twelve-Month Mortality
J PERS MED. 2022; 12(2): 320
Doi: 10.3390/jpm12020320
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Andreas Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: Stroke associated with transcatheter aortic valve replacement (TAVR) is a potentially devastating complication. Until recently, the Sentinel (TM) Cerebral Protection System (CPS; Boston Scientific, Marlborough, MA, USA) has been the only commercially available device for mechanical prevention of TAVR-related stroke. However, its effectiveness is still undetermined. Objectives: To explore the impact of Sentinel (TM) on stroke rate, length of hospital stay (LOS), and twelve-month mortality in a single-center, real-world, all-comers TAVR cohort. Material and Methods: Between January 2019 and August 2020 consecutive patients were assigned to TAVR with or without Sentinel (TM) in a 1:1 fashion according to the treating operator. We defined as primary endpoint clinically detectable cerebrovascular events within 72 h after TAVR and as secondary endpoints LOS and 12-month mortality. Logistic and linear regression analyses were used to assess associations of Sentinel (TM) use with endpoints. Results: Of 411 patients (80 & PLUSMN; 7 y/o, 47.4% female, EuroSCORE II 6.3 & PLUSMN; 5.9%), Sentinel (TM) was used in 213 (51.8%), with both filters correctly deployed in 189 (46.0%). Twenty (4.9%) cerebrovascular events were recorded, ten (2.4%) of which were disabling strokes. Patients with Sentinel (TM) suffered 71% less (univariate analysis; OR 0.29, 95%CI 0.11-0.82; p = 0.02) and, respectively, 76% less (multivariate analysis; OR 0.24, 95%CI 0.08-0.76; p = 0.02) cerebrovascular events compared to patients without Sentinel (TM). Sentinel (TM) use was also significantly associated with shorter LOS (Regression coefficient -2.47, 95%CI -4.08, -0.87; p < 0.01) and lower 12-month all-cause mortality (OR 0.45; 95%CI 0.22-0.93; p = 0.03). Conclusion: In the present prospective all-comers TAVR cohort, patients with Sentinel (TM) use showed (1) lower rates of cerebrovascular events, (2) shortened LOS, and (3) improved 12-month survival. These data promote the use of a CPS when implanting TAVR valves.
- Find related publications in this database (Keywords)
- Sentinel (TM) Cerebral Protection System
- transcatheter aortic valve replacement
- stroke
- mortality